It’s a $1.6 trillion question: Which impact investment practices and characteristics truly generate the positive outcomes that investors and stakeholders want to see? With a 21 percent compound annual ...

There is a long, quiet history of courts leveraging public health scholarship to overcome structural biases. As jurisprudence has evolved, the main, and arguably sole, tool available to combat ...

Projected savings from biosimilar natalizumab were $452,611 over 3 years, driven by decreased drug acquisition costs and a utilization shift from reference to biosimilar natalizumab. Objectives: ...

Managing system risk is paramount for organizations to protect their data and ensure operational continuity. Security Impact Analysis (SIA) is a critical component of this process, offering a ...

The introduction of lebrikizumab, a novel monoclonal antibody targeting interleukin-13 for severe atopic dermatitis (AD), was associated with cost savings of approximately €3.3 million over 3 years ...